InspireMD, Inc. (NSPR): who owns it and who trades it
As of Nov 16, 2026, NSPR insiders reported 12 open-market sales worth $127K and 15 purchases worth $408K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Shane Thomas Gleason (Chief Commercial Officer), with $127K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling InspireMD
From the latest filingsOverall: about as much buying as selling. Famous investors mostly sold. Funds mostly bought. Insiders was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns NSPR
36 funds and institutions reported NSPR shares worth $17.4M at the end of Q2 2026, about 53% of the company. The largest holder is Nantahala Capital Management, LLC with 14.4%.
Funds and institutions (13F) 53%Everyone else 47%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Nantahala Capital Management, LLC | 6.75M | 14.43% | $4.7M | +100% |
| Rosalind Advisors, Inc. | 3.91M | 8.35% | $2.7M | No change |
| Aberdeen Group plc | 3.70M | 7.90% | $2.6M | +17% |
| Orbimed Advisors LLC | 3.13M | 6.70% | $2.2M | No change |
| Parkman Healthcare Partners LLC | 2.42M | 5.16% | $1.7M | No change |
| Marshall Wace, LLP | 1.86M | 3.98% | $1.3M | No change |
| Soleus Capital Management, L.P. | 1.05M | 2.23% | $732K | No change |
| Pura Vida Investments, LLC | 450,517 | 0.96% | $315K | No change |
| Ingalls & Snyder LLC | 368,800 | 0.79% | $258K | -3% |
| Affiance Financial, LLC | 250,370 | 0.53% | $175K | No change |
| Velan Capital Investment Management LP | 148,138 | 0.32% | $104K | -93% |
| BlackRock, Inc. | 122,993 | 0.26% | $86.1K | +53% |
| Renaissance Technologies LLC | 112,832 | 0.24% | $79K | +541% |
| Creative Planning | 108,964 | 0.23% | $76.3K | +453% |
| Schonfeld Strategic Advisors LLC | 99,275 | 0.21% | $69.5K | New |
| Hrt Financial LP | 59,754 | 0.13% | $41K | New |
| XTX Topco Ltd | 49,029 | 0.10% | $34.3K | +297% |
| Centiva Capital, LP | 44,123 | 0.09% | $30.9K | +78% |
| Cambridge Investment Research Advisors, Inc. | 40,332 | 0.09% | $28K | New |
| Millennium Management LLC | 37,677 | 0.08% | $26.4K | -66% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, NSPR insiders reported $408K of open-market purchases and $127K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| May 27, 2026 | Paul Stuka | Director | Purchase | 20,000 | $0.88 | $17.6K | Form 4 |
| May 19, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 22,778 | $1.01 | $23K | Form 4 |
| May 14, 2026 | Paul Stuka | Director | Purchase | 5,000 | $1.15 | $5.8K | Form 4 |
| May 13, 2026 | Paul Stuka | Director | Purchase | 10,000 | $1.16 | $11.6K | Form 4 |
| May 12, 2026 | Marvin Slosman | CEO | Purchase | 21,000 | $1.20 | $25.2K | Form 4 |
| May 11, 2026 | Paul Stuka | Director | Purchase | 10,000 | $1.19 | $11.9K | Form 4 |
| May 8, 2026 | Paul Stuka | Director | Purchase | 65,626 | $1.16 | $76.1K | Form 4 |
| May 7, 2026 | Scott R. Ward | Director | Purchase | 73,255 | $1.15 | $84.2K | Form 4 |
| May 7, 2026 | Paul Stuka | Director | Purchase | 6,378 | $1.15 | $7.3K | Form 4 |
| May 7, 2026 | Gary S Roubin | Director | Purchase | 90,000 | $1.18 | $106K | Form 4 |
| May 6, 2026 | Scott R. Ward | Director | Purchase | 15,995 | $1.15 | $18.4K | Form 4 |
| May 6, 2026 | Paul Stuka | Director | Purchase | 1,517 | $1.12 | $1.7K | Form 4 |
| Feb 2, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 2,941 | $1.59 | $4.7K | Form 4 |
| Feb 2, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 2,000 | $1.60 | $3.2K | Form 4 |
| Jan 30, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 2,900 | $1.63 | $4.7K | Form 4 |
| Jan 29, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 5,000 | $1.65 | $8.2K | Form 4 |
| Jan 28, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 12,395 | $1.65 | $20.5K | Form 4 |
| Jan 27, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 4,781 | $1.66 | $7.9K | Form 4 |
| Jan 22, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 8,411 | $1.57 | $13.2K | Form 4 |
| Jan 21, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 17,593 | $1.62 | $28.5K | Form 4 |
| Jan 20, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 2,955 | $1.59 | $4.7K | Form 4 |
| Jan 16, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 2,250 | $1.61 | $3.6K | Form 4 |
| Jan 15, 2026 | Shane Thomas Gleason | Chief Commercial Officer | Sale | 2,909 | $1.58 | $4.6K | Form 4 |
| Dec 9, 2025 | Paul Stuka | Director | Purchase | 2,710 | $1.81 | $4.9K | Form 4 |
| Dec 9, 2025 | Paul Stuka | Director | Purchase | 5,073 | $1.81 | $9.2K | Form 4 |
| Dec 5, 2025 | Paul Stuka | Director | Purchase | 5,073 | $1.86 | $9.4K | Form 4 |
| Dec 4, 2025 | Paul Stuka | Director | Purchase | 10,130 | $1.85 | $18.7K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Paul Stuka | Director | $174K | – | May 27, 2026 |
| Shane Thomas Gleason | Chief Commercial Officer | – | $127K | May 19, 2026 |
| Gary S Roubin | Director | $106K | – | May 7, 2026 |
| Scott R. Ward | Director | $103K | – | May 7, 2026 |
| Marvin Slosman | CEO and President, Director | $25.2K | – | May 12, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
NSPR short interest
Low short interest. 0.5% of NSPR shares are sold short: about 1 share in 185. Over the last 12 reports the number of shares short went up 616%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 251,530 NSPR shares were sold short, 0.5% of the shares outstanding, up 210.9% from the report before. At the average daily volume of 329,636 shares, buying them all back would take about 1.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 251,530 | 0.54% | +211% | 329,636 | 1.0 |
| Oct 15, 2026 | 80,900 | 0.17% | +260% | 150,407 | 1.0 |
| Sep 30, 2026 | 22,466 | 0.05% | -11% | 70,548 | 1.0 |
| Sep 15, 2026 | 25,364 | 0.05% | -35% | 41,419 | 1.0 |
| Aug 31, 2026 | 38,879 | 0.08% | -54% | 106,585 | 1.0 |
| Aug 14, 2026 | 85,336 | 0.18% | -2% | 102,980 | 1.0 |
| Jul 31, 2026 | 87,281 | 0.19% | +14% | 34,710 | 2.5 |
| Jul 15, 2026 | 76,873 | 0.16% | +3% | 85,596 | 1.0 |
| Jun 30, 2026 | 74,465 | 0.16% | +42% | 88,802 | 1.0 |
| Jun 15, 2026 | 52,595 | 0.11% | +192% | 186,339 | 1.0 |
| May 29, 2026 | 18,004 | 0.04% | -49% | 197,089 | 1.0 |
| May 15, 2026 | 35,122 | 0.08% | -16% | 1.23M | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
InspireMD company events
InspireMD filed 14 reports on Form 8-K in the last 12 months, 6 of them about an important change (leadership, listing). The latest was on Sep 21, 2026.
- Sep 21, 2026AgreementInspireMD, Inc. entered into amendments with certain of the holders of the Company’s existing warrants to purchase common stock, par value $0.0001 per share, consisting of (i) Series J warrants to purchase up to 9,543,952 shares of Common Stock and (ii) Series K warrants to purchase up to 9,543,947… Filing
- Aug 17, 2026ResultsReleased financial results. Filing
- Jul 29, 2026LeadershipInspireMD, Inc. provided notice to Shane Gleason, the Company’s Chief Commercial Officer, that his position has been eliminated. Filing
- Jul 23, 2026ListingInspireMD, Inc. received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC notifying the Company that it is not in compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2), which… Filing
- Jul 2, 2026LeadershipMr. Raymond W. Cohen, a Class III member of the board of directors of InspireMD, Inc., a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, tendered his resignation from the Board, effective July 1, 2026. Filing
- Jun 11, 2026AnnouncementShared information with investors. Filing
- Jun 3, 2026VoteReported shareholder vote results. Filing
- May 22, 2026LeadershipMr. Paul Stuka notified InspireMD, Inc. of his decision to not seek reelection as a Class I director of the Board of Directors of the Company at the Company’s 2027 Annual Meeting of Stockholders and to retire from the Board. Filing
- May 4, 2026ResultsReleased financial results. Filing
- May 1, 2026AnnouncementOf this Current Report on Form 8-K. Filing
- Apr 3, 2026AgreementInspireMD, Inc. entered into an Equity Distribution Agreement with BTIG, LLC, as sales agent, pursuant to which the Company may offer and sell, from time to time, at its option, through or to BTIG shares of the Company’s common stock, $0.0001 par value per share. Filing
- Mar 18, 2026ResultsReleased financial results. Filing
- Mar 4, 2026LeadershipInspireMD, Inc. provided a notice of dismissal to Andrea Tommasoli, the Company’s Chief Operating Officer. Filing
- Dec 19, 2025LeadershipKathryn Arnold, a Class III member of the board of directors of InspireMD, Inc. (the “Board” and the “Company”, respectively), a member of the compensation committee of the Board, the nominating and corporate governance committee of the Board and the research and development committee of the Board… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
InspireMD financials
Famous investors that hold NSPR
3 of the 50 well-known investors we track reported holding NSPR in their latest 13F filing. The largest position is Jim Simons's, worth $58.7K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 87,892 | $58.7K | 0.0% | -22% |
| Israel Englander · Millennium Management | Q3 2026 | 21,760 | $14.6K | 0.0% | -42% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 18,916 | $12.7K | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about InspireMD, Inc. (NSPR) stock
Who owns the most NSPR stock?
The largest reported owner of InspireMD, Inc. (NSPR) is Nantahala Capital Management, LLC, with 14.4% of the company. In total, 36 funds and institutions reported holding NSPR at the end of Q2 2026, together about 53% of the shares. See the largest owners.
Are NSPR insiders buying or selling?
In the last 12 months, NSPR insiders reported 15 open-market purchases worth $408K and 12 sales worth $127K. The latest trade was on May 27, 2026. See every trade.
What is the short interest in NSPR?
As of Oct 30, 2026, 251,530 NSPR shares were sold short, 0.5% of the shares outstanding, up 210.9% from the report before. At the average daily volume of 329,636 shares, buying them all back would take about 1.0 trading days (days to cover). See the history.
Which famous investors hold NSPR?
3 of the 50 well-known investors we track reported NSPR in their latest 13F filing, including Jim Simons, Israel Englander, Ken Griffin. The largest position is worth $58.7K. See all holders.
Executive pay
InspireMD's chief executive was paid a total of $3.1M for the year ended Dec 31, 2025, down 6% from $3.3M the year before. In the last 12 months, InspireMD's executives and directors bought $408K of stock on the open market and sold $289K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.